GlassScriptPhysician profile
Mason W Mileur
NPI 1417268251
$6,235.14
in general payments reported to CMS, 2019-2025
47 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $169 · 2021: $581 · 2022: $855 · 2023: $1,342 · 2024: $1,624 · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,204 · Education: $39.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,203.84 |
| Education | $39.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,100.62 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $704.98 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $495.04 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $474.92 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $376.06 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.86 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $242.78 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $217.37 | 2021-2024 | Spravato |
| Abbott Laboratories | $207.05 | 2021-2025 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.26 | 2020-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $172.79 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $141.67 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $129.48 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.45 | 2021-2024 | Trintellix |
| Acerus Pharmaceuticals Corporation | $95.83 | 2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mason Mileur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.